Skip to main content
. 2021 Jan 11;10:585216. doi: 10.3389/fonc.2020.585216

Figure 5.

Figure 5

The change of CD54highCD181low neutrophils from myelodysplastic syndromes (MDS) patients at new diagnosis (ND) and post-therapy (PT). (A) Low risk MDS patient (n = 12). P > 0.05. (B) high risk MDS patients without good response (CR+PR) (N = 6). P > 0.05. (C) high risk MDS patients with good response (CR+PR) (N = 4). P < 0.05.